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ABSTRACT
Background. Outcomes after acute kidney injury (AKI) are
well described, but not for those already under nephrology
clinic care. This is where discussions about kidney failure risk
are commonplace. We evaluated whether the established kidney
failure risk equation (KFRE) should account for previous AKI
episodes when used in this setting.
Methods. This observational cohort study included 7491 people
referred for nephrology clinic care in British Columbia in 2003–
09 followed to 2016. Predictors were previous Kidney Disease:
Improving Global Outcomes–based AKI, age, sex, proteinuria,
estimated glomerular ﬁltration rate (eGFR) and renal diagnosis.
Outcomes were 5-year kidney failure and death. We developed
cause-speciﬁc Cox models (AKI versus no AKI) for kidney fail-
ure and death, stratiﬁed by eGFR (</30mL/min/1.73m2).
We also compared prediction models comparing the 5-year
KFRE with two reﬁtted models, one with and one without AKI
as a predictor.
Results. AKI was associated with increased kidney failure
(33.1% versus 26.3%) and death (23.8% versus 16.8%) (P
< 0.001). In Cox models, AKI was independently associated
with increased kidney failure in those with an eGFR 30mL/
min/1.73m2 {hazard ratio [HR] 1.35 [95% conﬁdence interval
(CI) 1.07–1.70]}, no increase in those with eGFR <30mL/min/
1.73m2 ([HR 1.05 95% CI 0.91–1.21)] and increased mortality
in both subgroups [respective HRs 1.89 (95% CI 1.56–2.30) and
1.43 (1.16–1.75)]. Incorporating AKI into a reﬁtted kidney fail-
ure prediction model did not improve predictions on compari-
son of receiver operating characteristics (P¼ 0.16) or decision
curve analysis. The original KFRE calibrated poorly in this set-
ting, underpredicting risk.
Conclusions. AKI carries a poorer long-term prognosis among
those already under nephrology care. AKI may not alter kidney
failure risk predictions, but the use of predictionmodels without
appreciating the full impact of AKI, including increased
mortality, would be simplistic. People with kidney diseases have
risks beyond simply kidney failure. This complexity and vari-
ability of outcomes of individuals is important.
Keywords: acute kidney injury, epidemiology, kidney failure,
prediction, prognosis
INTRODUCTION
Acute kidney injury (AKI) is a serious condition [1] with estab-
lished risk factors [age, chronic kidney disease (CKD) and vas-
cular comorbidities] [2]. It is associatied with increased long-
term renal replacement therapy (RRT) [3], mortality [4] and
CKD progression even when post-AKI kidney function returns
to ‘normal’ [5]. However, most publications focus on hospital-
ized patients cared for by generalists. There are limited data re-
garding the impact of episodes of AKI among people already
under the care of nephrologists [6]. Those under the regular
care of nephrologists are a prioritized group, often with a
known underlying renal diagnosis. They may undergo more
frequent blood tests, which may increase the likelihood of find-
ing incidental changes in serum creatinine (i.e. not prompted
by clinical condition) or non-meaningful changes in creatinine
(false-positive AKI episodes) [7].
Clinical evidence is important for guiding clinical decisions
both directly (risk prediction tools [8–10]) and indirectly
(informing clinical guidelines [2]). Risk tools, such as the kidney
failure risk equation (KFRE), can be helpful adjuncts for triag-
ing patients and reducing waiting times [11]. However, clini-
cians should be mindful that evidence generated from one
context (people in an unselected population) may not be gener-
alizable to others (selected people already in nephrology clinics)
[12]. It is therefore important to understand the prognostic
implications of small changes in creatinine that occur among
people under nephrology clinic care and whether these implica-
tions vary according to underlying renal diagnosis, age or other
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parameters. It is also unclear if, in the setting of recent AKI,
prognosis can still be adequately described by established deci-
sion tools [8–10] or if previous episodes of AKI should be fac-
tored in, particularly when deciding if someone with recent
AKI but otherwise preserved kidney function should receive
ongoing clinic care [13].
The purpose of this analysis was to evaluate the impact of
small changes in serum creatinine (AKI episodes according to
established definitions) on the long-term outcomes of those al-
ready under the care of nephrologists. First, we determined
whether AKI was independently associated with kidney failure
or death (a competing risk) in this population. Then we evalu-
ated the incremental improvement of adding AKI to established
predictors in the KFRE for predicting kidney failure among
those already under nephrology care.
MATERIALS AND METHODS
Population
The Patient Records and Outcome Management
Information System (PROMIS) collects health data from all
people with kidney disease who receive care from a nephrolo-
gist in a kidney care clinic in any of 41 renal units in British
Columbia (population 4.5 million) [14]. People receive tests
with protocolized regularity with minimum blood test frequen-
cies in accordance with international guidelines [15]. This
unique province-wide dataset allows insight into the prognosis
of people directly cared for by nephrologists. For these people,
the dataset includes blood tests both from clinic visits and hos-
pitalizations. For this analysis, the population comprised people
>18 years of age who entered follow-up in PROMIS from 1
January 2003 to 31 July 2009 and who remained alive after a 2-
year observation period without need for long-term RRT or es-
timated glomerular filtration rate (eGFR) <15mL/min/
1.73m2. The study was approved by the Providence Health
Care Research Ethics Board.
Exposure
The exposure was an episode of AKI during 2 years of initial
observation from the date of first entry into PROMIS. The com-
parator was no AKI episode. We used a Kidney Disease:
Improving Global Outcomes (KDIGO)-based definition for
AKI incorporating a hierarchy of serum creatinine changes.
This definition for AKI has previously been described in detail
elsewhere [4]. Briefly, the definition involves one of three crite-
ria: (i) serum creatinine 1.5 times higher than the median of
all creatinine values 8–90 days ago or 91–365 days ago if no tests
between 8 and 90 days; (ii) serum creatinine 1.5 times higher
than the lowest creatinine within 7 days and (iii) serum creati-
nine>26mmol/L higher than the lowest creatinine within 48 h.
Outcomes
Subsequent outcomes were kidney failure and death without
kidney failure. Kidney failure was defined as either long-term
RRT or an eGFR <15mL/min/1.73m2 sustained for at least
90 days [15]. For eGFR we used the Chronic Kidney Disease
Epidemiology Collaboration (CKD-EPI) creatinine equation
[16].
Follow-up
To avoid immortal time bias, follow-up started at the end of
a 2-year observation period (illustrated in Supplementary data,
Figure S1). Follow-up continued until the first outcome or for a
further 5 years (i.e. up to July 2016).
Covariates
Covariates were age, sex and eGFR at baseline and after the
2-year observation period, proteinuria, blood pressure (systolic
and diastolic), history of diabetes mellitus and primary renal di-
agnosis as recorded at baseline in the PROMIS database.
Proteinuria was determined using urine albumin/creatinine
measurements [15].
Statistical analyses
We reported the number of people who developed AKI by
each of the three main definition critera, by AKI severity stage
and by the presence of recurrent episodes. We compared the
characteristics of people with and without AKI during the 2-
year observation period and determined the proportion of peo-
ple with kidney failure, death without kidney failure (competing
risk) or alive without kidney failure after 5 years of follow-up
(i.e. 7 years from the date of entry into PROMIS). For clarity of
presentation in the characteristics tables, proteinuria was
grouped as severe, moderate, none/mild and unrecorded (albu-
min:creatinine ratio >300, 30–300, <30mg/g and unrecorded,
respectively) and eGFR was grouped with CKD stage groups
based on KDIGO CKD criteria [15]. Both covariates were ana-
lysed continuously in the prediction models.
For those with and without AKI, we plotted cumulative inci-
dence functions for kidney failure stratified by age, eGFR and
underlying renal diagnosis (recognized predictors of kidney
failure) [9]. We fitted Cox models for the cause-specific hazard
ratio (HR) (AKI versus no AKI) for kidney failure and the com-
peting risk of death without kidney failure adjusted for covari-
ates. Continuous variables were assessed for non-linearity
visually and using fractional polynomials [17]. The propor-
tional hazards assumption was verified by ln{ln(survival)}
plots.
As kidney failure is potentially a rare endpoint, in a sensitiv-
ity analysis we used a recognized alternative endpoint: 30% sus-
tained decrease in eGFR or long-term RRT [18]. In addition, as
both competing outcomes may vary by AKI phenotype, in sub-
group analyses we limited our definition of AKI to the third cri-
terion (small changes of serum creatinine >26mmol/L in 48h),
to only those with AKI severity stage 1 (stages 2 and 3 excluded)
and to only those with recurrent AKI episodes during the
2-year observation period.
For prediction models of 5-year kidney failure risk we exter-
nally validated the widely used 5-year KFRE [8, 9] in the ne-
phrology clinic cohort and compared its performance with two
refitted models developed in the same cohort. For one refitted
model we used the same variables as the four-variable KFRE
(age, sex, eGFR and albumin:creatinine ratio) and in the second
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we added AKI as an additional variable. As death is a competing
risk for kidney failure, competing risks regression models were
constructed using the Fine and Gray technique [19]. The associ-
ation of AKI (versus no AKI) with poor outcomes is greater at
higher eGFRs [4, 5], and people with an eGFR <30mL/min/
1.73m2 typically receive regular nephrology clinic care (per cur-
rent guidelines) [15] for complications of CKD even if kidney
failure risk is low. Therefore our analyses were stratified by
eGFR (</30mL/min/1.73m2) and prediction models assess-
ing incremental improvement in AKI focused on those with
eGFR30mL/min/1.73m2.
To assess model performance we compared discrimination
of these models by calculating the area under the receiver oper-
ated characteristics curve (AUC). The value of an AUC lies be-
tween 0.5 and 1, with 0.5 indicating no better than a coin toss
and 1 indicating perfect discrimination between those with and
without an outcome [20]. We also evaluated calibration by plot-
ting the mean observed proportion of people with the outcomes
against the predicted probabilities of the outcome by increasing
tenths of predicted probabilities. Further, for the external vali-
dation of KFRE we calculated the calibration slope. This is the
coefficient of a regression model containing the linear predictor
of the KFRE [21]. A slope close to 1 indicates excellent agree-
ment, whereas a slope <1 may indicate unduly extreme predic-
tions and a slope >1 may indicate predictions that do not vary
sufficiently for that model [22, 23].
Even if a model discriminates well overall, this may not lead
to better decisions about the appropriate threshold needed for
clinical use. For instance, a new model may be useful at a risk
threshold cut-off of 80%, but if intervention is recommended
when the risk of an outcome is lower (e.g. 10%), the samemodel
may no longer be useful [24]. Decision curve analysis is a
method of assessing the clinical usefulness of different models
at an appropriate (preferably prespecified) threshold compared
with strategies of ‘treat all’ or ‘treat none’ [25]. It is a plot of the
‘net benefit’ of each model, which is a trade-off between true
positives and false positives at different thresholds described by
the equation below [25]. ‘Treatment’ could be a new drug, a
procedure or a decision to follow-up.











Elsewhere, a 5-year KFRE risk threshold 3% has been sug-
gested and used as a criterion for eligible transition from primary
care to nephrology care among people with an eGFR 30mL/
min/1.73m2 [11]. Decision curve analysis should therefore show
a net benefit at this threshold. Analyses were performed in Stata
SE 13 (StataCorp, College Station, TX, USA) [26].
RESULTS
Population
From a population of 4.5 million, there were 9531 people
who were registered into a nephrologist’s care in PROMIS
between 1 January 2003 and 31 July 2009, including 8726 who
were still alive after 2 years of observation. As shown in
Figure 1, after excluding those who were already receiving long-
term RRT or had an eGFR <15mL/min/1.73m2, 7491 people
met the study inclusion criteria, including 995 (13.3%) with an
episode of AKI. Subsequent follow-up was for a median of
5 years, or 27 742 patient-years. A breakdown of AKI by defini-
tion criteria, severity stage and recurrence of AKI episodes is
provided in Supplementary data, Table S1.
Baseline characteristics of people with and without AKI
Table 1 describes the characteristics of people with and with-
out an episode of AKI during the initial 2-year observation pe-
riod prior to study follow-up. The proportion of people with
AKI was no greater among older patients than younger patients
and no different for women and men. In this cohort, AKI epi-
sodes occurred more frequently among those with baseline
eGFR 60 versus <30mL/min/1.73m2 (18.8% versus 13.2%).
There were also more AKI episodes among people with severe
proteinuria and high blood pressure. Occurrence of AKI varied
by underlying renal diagnosis (from 4.4% of people with poly-
cystic kidney disease to 17.0% of people with diabetes-related
kidney disease).
Overall 5-year outcomes among people with and
without AKI
Five-year outcomes are reported in Table 2, stratified by age,
sex, eGFR and other characteristics. Overall, people with AKI in
the preceding 2 years (versus no AKI) had an increased risk of
kidney failure (33.1% versus 26.3%) and the competing out-
come of death (23.8% versus 16.8%) (v2 P< 0.001; Table 2).
This pattern was present irrespective of age, sex, eGFR (as mea-
sured after the 2-year observation period), proteinuria and renal
diagnosis.
Cumulative rates of kidney failure and the competing
event of death
Figure 2 and Supplementary data, Figures S2 and S3 show
the cumulative incidences of kidney failure and death without
kidney failure in those with and without AKI, stratified by age,
eGFR and primary renal diagnosis, respectively. Stratification
by age showed an increase in both kidney failure and death after
AKI in all age groups (Figure 2). Those 80 years of age
were more likely to die than reach kidney failure, whereas
death was uncommon among those <60 years of age. AKI was
also associated with poorer outcomes irrespective of eGFR
(Supplementary data, Figure S2) and renal diagnosis
(Supplementary data, Figure S3), but the occurrence of the
competing event of death varied between subgroups.
Independent association between AKI and kidney
failure and death
Table 3 describes the independent role of AKI (versus no
AKI) in kidney failure and the competing event of death with
stepwise adjustment for age, sex, eGFR, proteinuria and pri-
mary renal diagnosis. As eGFR has previously been shown to
modify the prognosis of AKI [4, 5, 27], two separate models
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were built for those with eGFR 30mL/min/1.73m2 and those
with eGFR <30mL/min/1.73m2. Irrespective of eGFR, AKI
was associated with kidney failure in univariable analysis, how-
ever, in multivariable analysis the excess risk associated with
AKI among those with eGFR <30mL/min/1.73m2 could be
explained by adjusting for covariates [HR 1.05 (95% CI 0.91–
1.21)]. By comparison, among those with eGFR 30mL/min/
1.73m2, even after adjusting for potential confounders, those
with previous AKI remained at an excess risk [HR 1.35 (95% CI
1.07–1.70)]. In a sensitivity analysis using a recognized alterna-
tive metric of CKD progression (30% eGFR decline or long-
term RRT), there was a similar pattern of excess risk for those
with AKI and eGFR 30mL/min/1.73m2 (Supplementary
data, Table S2). In subgroup analyses (Supplementary data,
Tables S3–S5) we found a similar pattern of a large excess risk
of death and small excess risk of kidney failure even when our
definition of AKI was restricted to a criterion involving small
creatinine changes (>26mmol/L) within 48 h. Among those
with eGFR 30mL/min/1.73m2, the excess kidney failure risk
was substantial for the minority of people who had recurrent
AKI episodes [adjusted HR 2.34 (95% CI 1.50–3.66);
Supplementary data, Table S5].
5 -Year KFRE and refitted models with and without AKI
added
Table 4 compares three models for predicting kidney failure
among people with eGFR 30mL/min/1.73m2: external vali-
dation of the 5-year KFRE, a refitted model using the same vari-
ables (age, sex, eGFR and proteinuria) developed using the Fine
and Gray technique [19] and a second refitted model incorpo-
rating AKI as an additional predictor. As shown by the calibra-
tion plot (Figure 3) and the calibration slope significantly
FIGURE 1: Development of the study population.
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different from 1 (Table 4), the KFRE was miscalibrated and
underpredicted kidney failure in this cohort. For discrimina-
tion, respective AUCs were 0.701, 0.715 and 0.716. Using deci-
sion curve analysis, the refitted model with AKI was no better
than the refitted model without AKI (Figure 4). KFRE was infe-
rior to either refitted model or a ‘treat all’ approach (i.e. clinical
follow-up of all people) if used at any risk threshold between
0% and 10%, as suggested in previous studies [11]. Fitting a sep-
arate model that included recurrent AKI as a predictor also did
not greatly alter discrimination (AUC 0.718).
DISCUSSION
This large long-term analysis of a provincial Canadian cohort is
the first to predict kidney failure risk after AKI among people
already undergoing nephrology clinic follow-up. There are two
important messages for nephrologists.
First, small acute creatinine changes of AKI in people al-
ready under nephrology care are associated with a small inde-
pendent increased risk of kidney failure and a large competing
risk of death, irrespective of age or renal diagnosis.
Incorporating AKI into kidney failure risk prediction models
does not improve predictions, but the reason is likely to be be-
cause many people with AKI die before kidney failure. Thus,
while AKI may not substantially alter kidney failure risk predic-
tions, the use of prediction models in individuals without an ap-
preciation of the full impact of AKI would be simplistic. Thus
the notion of ‘competing risk of death’ needs to be incorporated
more overtly into clinical thinking and discussions with
patients.
Second, the established KFRE calibrated poorly when used
in people with preserved eGFR (30mL/min/1.73m2) under
nephrology clinic follow-up, leading to substantially
underpredicted risks. A strategy of caring for all would be better
than using the KFRE at a threshold of 3% to prioritize people
with eGFR 30mL/min/1.73m2 who should continue to re-
ceive nephrology care. Reasons for this are unclear, but people
with eGFR 30mL/min/1.73m2 who are followed by nephrol-
ogists may already be a high-risk group for reasons not
completely captured by the KFRE. In keeping with this, AKI
did not vary with age in this cohort, even though old age is an
established risk factor for AKI (and death). This suggests selec-
tive nephrology follow-up of those in the general population
who were most likely to develop kidney failure (rather than
die). This complexity indicates that caution is needed when ne-
phrologist apply prediction tools to individual people in specific
clinical contexts.
This analysis shows that clinicians should understand better
the substantial competing risk of death occurring after AKI be-
fore kidney failure can develop. That is, AKI may serve as a ‘sig-
nal’ for adverse outcomes, including but not limited to kidney
failure. As illustrated in the cumulative incidence plots of this
study, this increased mortality is present irrespective of age,
eGFR or underlying renal diagnosis. The substantial competing
outcomes after AKI should prompt us to consider the numer-
ous reasons, other than simply kidney failure risk, that people
with kidney disease may benefit from nephrology care.
Nephrology care may include prevention of recurrent acute ill-
ness episodes, prevention of CKD complications, optimization
of cardiovascular profile, fluid balance and alleviation of symp-
toms. To date, there remains little evidence describing the value
of nephrology care in optimizing cardiovascular risk for those
with advanced CKD or preventing AKI due to drugs or con-
trast. Future work should examine this for the high-risk group
identified in this analysis of AKI survivors.
Our analysis also highlights the importance of clinical con-
text when evaluating AKI. Even if there is a similar pattern of
increased risk after AKI across numerous studies, absolute risk
Table 1. Characteristics of people with and without AKI during the 2-year
observation period
Overall, N AKI in first
2 years
No AKI in first
2 years
N % N %
N 7491 995 6496
Age (years)
80 1488 162 16.3 1326 20.4
60–79 4365 617 62.0 3748 57.7
<60 1638 216 21.7 1422 21.9
Sex
Female 3451 531 53.4 3509 54.0
Male 4040 464 46.6 2987 46.0
Baseline eGFR (mL/min/1.73m2
<30 2672 352 35.4 2320 35.7
30–44 2954 367 36.9 2587 39.8
45–59 1142 140 14.1 1002 15.4
60 723 136 13.7 587 9.0
Baseline proteinuria
Severe 1415 229 23.0 1186 18.3
Moderate 1873 271 27.2 1602 24.7
None/mild 1570 207 20.8 1363 21.0
Not tested 2633 288 28.9 2345 36.1
Systolic blood pressure (mmHg
160 911 134 13.5 777 12.0
120–160 3603 487 48.9 3116 48.0
<120 1235 177 17.8 1058 16.3
Not recorded 1742 197 19.8 1545 23.8
Diastolic blood pressure (mmHg
100 148 24 2.4 124 1.9
60–100 5014 687 69.0 4327 66.6
<60 587 87 8.7 500 7.7
Not recorded 1742 197 19.8 1545 23.8
Diabetes mellitus
Yes 4511 707 71.1 3804 58.6
No 2980 288 28.9 2692 41.4
Primary renal diagnosis
Diabetes mellitus 1220 207 20.8 1013 15.6
Glomerulonephritis 368 44 4.4 324 5.0
Interstitial/intrinsic renal 699 101 10.2 598 9.2
Multisystem disorder 430 67 6.7 363 5.6
Polycystic kidney disease 159 7 0.7 152 2.3
Vascular/hypertension 1636 225 22.6 1411 21.7
Uncertain aetiology 1059 134 13.5 925 14.2
Not recorded 1920 210 21.1 1710 26.3
Year of ﬁrst follow-up
2003–06 3139 440 44.2 2699 41.5
2007–09 4352 555 55.8 3797 58.5
All people in this analysis were observed for 2 years for the development of AKI.
Baseline refers to covariate values at the beginning of a 2-year observation period prior
to study follow- up.
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differs depending on the clinical context. For instance, the AKI
definition in this analysis (in a nephrology clinic population)
was identical to that used in previous work (in a general popula-
tion), but in this analysis the risk of renal progression was sub-
stantially higher and the risk of mortality was lower [5].
Strengths of this analysis include the large sample size, cov-
ering an entire province in Canada. The novel focus on those
under nephrology care makes the findings particularly relevant
for practising nephrologists and multidisciplinary kidney care
clinics. The definition of AKI was comprehensive and KDIGO
based and modelling included measures of proteinuria that
are frequently unavailable in clinical AKI studies [3, 6, 28].
Moreover, an opportunity for eGFR to return to baseline after
AKI (necessary to avoid confusing non-recovery with progres-
sion) [5] was provided by using post-AKI episode eGFR values
in the analysis after the 2-year observation period. The analysis
also can be supported by recent population studies showing the
effect modification of AKI outcomes by eGFR in the USA and
UK [4, 27] and recent work illustrating the potential value of
updating risk prediction tools as new information arises [29].
The analysis also has limitations. This analysis involves AKI
occurring while under nephrology care and does not include
episodes of AKI occurring prior to nephrology referral (which
may have prompted referral). This may have led to an attenua-
tion of the association between AKI and outcomes of interest.
We recognize that clinical nephrology practices in British
Table 2. Subsequent 5-year outcomes among people with and without an episode of AKI in the previous 2-year observation period
AKI in previous 2 years No AKI in previous 2 years













N 7491 995 43.1 33.1 23.8 6496 56.9 26.3 16.8
Age (years
80 1488 162 35.8 27.2 37.0 1326 41.2 23.0 35.8
60–79 4365 617 41.0 33.4 25.6 3748 59.0 25.6 15.4
<60 1638 216 54.6 36.6 8.8 1422 66.0 30.8 3.2
Sex
Female 3451 531 49.8 30.0 20.3 3509 59.1 25.4 15.5
Male 4040 464 37.3 35.8 26.9 2987 55.0 27.0 18.0
Post-observation eGFRa (mL/min/1.73m2)
<30 3015 473 25.6 51.2 23.2 2542 31.9 47.7 20.4
30–44 2812 357 55.2 18.2 26.6 2455 66.3 15.4 18.2
45–59 1057 109 68.8 12.8 18.3 948 81.4 7.9 10.7
60 607 56 64.3 14.3 21.4 551 88.2 7.1 4.7
Post-observation proteinuriaa
Severe 1468 233 18.0 62.7 19.3 1235 24.3 57.1 18.6
Moderate 1824 277 34.2 29.6 36.1 1547 44.7 25.1 30.3
None/mild 1566 197 41.1 22.3 36.5 1369 63.7 12.9 23.4
Not tested 2633 288 73.3 19.8 6.9 2345 78.2 18.6 3.2
Systolic blood pressure (mmHg)
160 911 134 35.8 41.8 22.4 777 48.3 36.8 14.9
120–160 3603 487 40.2 41.7 18.1 3116 53.7 31.6 14.7
<120 1235 177 53.1 20.9 26.0 1058 58.4 23.9 17.7
Not recorded 1742 197 46.2 16.8 37.1 1545 66.7 11.8 21.6
Diastolic blood pressure (mmHg)
100 148 24 37.5 54.2 8.3 124 58.1 32.3 9.7
60–100 5014 687 43.7 36.7 19.7 4327 54.7 30.6 14.7
<60 587 87 33.3 35.6 31.0 500 45.4 31.6 23.0
Not recorded 1742 197 46.2 16.8 37.1 1545 66.7 11.8 21.6
Diabetes mellitus
Yes 4511 707 40.7 35.4 23.9 3804 52.7 30.8 16.5
No 2980 288 48.9 27.4 23.6 2692 62.8 19.9 17.3
Primary renal diagnosis
Diabetes mellitus 1220 207 34.8 50.2 15.0 1013 45.3 43.4 11.3
Glomerulonephritis 368 44 25.0 61.4 13.6 324 50.3 46.0 3.7
Interstitial/intrinsic renal 699 101 53.5 29.7 16.8 598 60.9 28.8 10.4
Multisystem disorder 430 67 37.3 38.8 23.9 363 59.2 20.4 20.4
Polycystic kidney disease 159 7 42.9 57.1 0.0 152 46.7 52.6 0.7
Vascular/hypertension 1636 225 49.3 25.3 25.3 1411 57.3 27.6 15.1
Uncertain aetiology 1059 134 44.0 29.1 26.9 925 63.3 20.5 16.1
Not recorded 1920 210 44.8 20.0 35.2 1710 60.2 12.3 27.4
Year of ﬁrst follow-up
2003–06 3139 440 44.5 32.3 23.1 2699 58.7 25.4 15.9
2007–09 4352 555 42.0 33.7 24.3 3797 55.6 26.9 17.5
All people in this analysis were observed for 2 years for the development of AKI. Outcomes refer to CKD stage 5 and death over the subsequent 5 years thereafter.
aRefers to the last measurement from the 2-year observation period.
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FIGURE 2: Cumulative incidence of kidney failure and death among those with and without AKI grouped by age (years).
Table 3. Independent role of previous AKI in subsequent kidney failure and competing risk of death
Comparison Subgroup Adjusted covariates AKI versus no AKI
for kidney failure, HR (95% CI)
AKI versus no AKI for death
without kidney failure, HR (95%
CI)
AKI versus no AKI eGFR< 30 – 1.24 (1.08–1.42) 1.34 (1.09–1.65)
AKI versus no AKI eGFR< 30 Age and sex 1.23 (1.07–1.42) 1.46 (1.19–1.79)
AKI versus no AKI eGFR< 30 Age, sex and eGFR 1.10 (0.95–1.26) 1.43 (1.17–1.76)
AKI versus no AKI eGFR< 30 Age, sex, eGFR and proteinuria 1.03 (0.89–1.18) 1.43 (1.16–1.76)
AKI versus no AKI eGFR< 30 Age, sex, eGFR, proteinuria and renal diagnosis 1.05 (0.91–1.21) 1.43 (1.16–1.75)
AKI versus no AKI eGFR 30 – 1.55 (1.23–1.94) 1.90 (1.57–2.30)
AKI versus no AKI eGFR 30 Age and sex 1.55 (1.24–1.95) 2.10 (1.73–2.54)
AKI versus no AKI eGFR 30 Age, sex and eGFR 1.43 (1.13–1.79) 2.05 (1.69–2.49)
AKI versus no AKI eGFR 30 Age, sex, eGFR and proteinuria 1.34 (1.07–1.69) 1.87 (1.54–2.27)
AKI versus no AKI eGFR 30 Age, sex, eGFR, proteinuria and renal diagnosis 1.35 (1.07–1.70) 1.89 (1.56–2.30)
Age as a linear term, eGFR-2, proteinuria in four KDIGO albuminuria categories of severe, moderate, normal/mild and not tested. AKI represents AKI occurring in a 2-year observation
period prior to study follow-up. eGFR and proteinuria status were determined from the last available sample at the end of the 2-year observation period. The outcome of kidney failure
represents a composite of long-term RRT or eGFR <15mL/min/1.73m2 sustained for at least 90 days. eGFR given in mL/min/1.73 m2.
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Columbia may vary from practices in other countries, although
our findings are broadly consistent with a methodologically
similar study using a UK cohort [5]. We also recognize that
as the covariates were obtained from routinely collected
health data, not all items were complete (e.g. proteinuria). This,
however, reflects real-world clinical practice in nephrology clin-
ics in British Columbia, where not all urine samples are sent for
quantification, e.g. when bedside urinalysis is normal. This
explains why those without a documented measure of protein-
uria had the best outcomes. Additional adjustment for a wider
range of comorbidities was also not possible, but we note that
wider comorbidities are not a component of the KFRE either.
Finally, we note that we tested our prediction models in just one
cohort, but this is sufficient for the purpose of our study: for
evaluating incremental risk with AKI as a predictor, we used
the same dataset and variables for two refitted models so that
the only difference between the models was the inclusion of the
predictor AKI. For evaluating the use of KFRE, we externally
validated an equation already studied in numerous population
datasets.
In conclusion, a history of AKI based on small creatinine
changes (versus no AKI) carries a poorer long-term prognosis for
all outcomes among those already under nephrology clinic care,
irrespective of the level of kidney function, age and renal diagno-
sis. People with CKD and AKI have risks beyond simply kidney
failure, including cardiovascular events and death. Clinical appre-
ciation of these other risks and targeted research to identify the
best strategies to modify risks in high-risk individulas is critical.
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Table 4. Five-year kidney failure risk prediction models for people with eGFR 30mL/min/1.73m2
Model Equation Calibration slopea AUC P-value for AUC
comparison with next
most complex model
Five-year KFRE 1 0.924ˆexp((0.2201 * (((age)/10) 7.036)) þ
(0.2467 * (sex0.5642))  (0.5567 * ((eGFR/5)
7.222)) þ ((0.451 * (lnACR5.137))))
0.44 (0.39–0.49) 0.701 (0.676–0.725) 0.02
Reﬁtted model without AKI 1 0.916ˆexp((0.3074 * ((age70)/10)) þ (0.1801
* ((eGFR30)/5)) þ (0.2227 * sex) þ (0.2292 *
lnACR))
1.00 (0.90–1.10) 0.715 (0.691–0.739) 0.16
Reﬁtted model with AKI 1 -0.918ˆexp((0.307 * ((age70)/10)) þ (0.179 *
((eGFR30)/5)) þ (0.2224 * sex) þ (0.228 * lnACR)
þ (0.148 * AKI2yr))
1.00 (0.90–1.10) 0.716 (0.692–0.741)
AKI2 yr represents AKI occurring in a 2-year observation period prior to study follow-up (1¼AKI, 0¼ no AKI). Age (in years), eGFR and proteinuria were determined from the last
available sample at the end of the 2-year observation period. Sex¼ 1 if male and 0 if female. The outcome of kidney failure represents a composite of long-term RRT or eGFR <15mL/
min/1.73m2 sustained for at least 90 days.
aCalibration slope should be expected to be equal to 1 in the development of reﬁtted models (apparent calibration). For external validation of the KFRE, a slope different from 1 indi-
cates miscalibration.
lnACR, natural logarithm of albumin:creatinine ratio (mg/g).
FIGURE 4: Decision curve analysis of 5-year kidney failure risk pre-
diction models for people with eGFR 30mL/min/1.73m2. KFRE
was inferior to a ‘treat all’ approach when the risk threshold was
<10%. AKI added no value as an additional predictor in a reﬁtted
model.
FIGURE 3: Calibration plots for the 5-year kidney failure risk equa-
tion and a reﬁtted model with AKI as an added predictor. Circles
represent the cohort grouped in increasing tenths of predicted prob-
abilities. KFRE underpredicted 5-year kidney failure in this cohort.
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